Sichuan Kelun-Biotech Biopharmaceutical First Half 2024 Earnings: Beats Expectations

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) First Half 2024 ResultsKey Financial Results Revenue: CN¥1.38b (up 32% from 1H 2023). Net income: CN¥310.2m (up from CN¥25.4m loss in 1H 2023). Profit margin: 22% (up from net loss in 1H 2023). EPS: CN¥1.41 (up from CN¥0.17 loss in 1H 2023). SEHK:6990 Earnings and Revenue Growth August 23rd 2024 All figures shown in the chart above are for the trailing 12 month (TTM) period Sichuan Kelun-Biotech Biopharmaceutical Revenues and Earnings…
Read More…

Source: https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-biopharmaceutical-first-half-2024-earn